0:00 据药明生物官微，药明生物与生诺医药1月29日共同宣布，双方就创新双特异性抗体SND006的工艺开发 和生产达成战略合作。SND006拟用于治疗炎症性肠病（IBD）等自身免疫性疾病。 ...

SHANGHAI, Jan. 26, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, jointly announced today the signing of a strategic collaboration agreement on the development and manufacturing of multiple next-generation bi-/multi-functional fusion programs from HanchorBio’s pip ...

Core Viewpoint - WuXi Biologics and Hanchor Bio, Inc. have signed a strategic cooperation agreement to jointly advance the development and production of next-generation bispecific and multispecific antibodies [1][7]. Group 1: Strategic Cooperation - The agreement entails WuXi Biologics providing end-to-end integrated services for biopharmaceutical development and production, including cell line development, process and bioassay development, formulation development, and GMP production [2][9]. - The collaboration aims to accelerate clinical translation processes, enhance CMC execution efficiency, and support Hanchor Bio's innovative fusion protein product portfolio based on the Fc-based design biopharmaceutical (FBDB™) platform for global scale development and production [4][12]. Group 2: Company Background - Hanchor Bio, established in December 2020, is a global clinical-stage biotechnology company focused on developing next-generation immunotherapies for oncology and autoimmune diseases [4][12]. - The FBDB™ platform supports the design of multifunctional biopharmaceuticals with diverse targeting mechanisms, aiming to activate both innate and adaptive immune pathways to overcome challenges associated with current anti-PD1/L1 immunotherapies [4][12]. - Hanchor Bio successfully provided proof-of-concept data in multiple in vivo tumor animal models using the FBDB™ platform [4][12]. - In September of the previous year, Hanchor Bio completed a capital increase of 160 million RMB to accelerate the development of multiple new drugs [4][12].

Core Viewpoint - Since January 20, WuXi Biologics (02269) has outperformed its mainland CRO peers and the overall healthcare sector, indicating its relative resilience in the market [1] Group 1: Company Performance - WuXi Biologics has shown better stock performance compared to mainland CRO peers and the broader healthcare sector since January 20 [1] - The company benefits from a more diversified shareholder structure, which helps mitigate geopolitical risk impacts [1] Group 2: Growth Potential - There is an increased visibility for accelerated growth before 2026, suggesting that the company's potential performance may exceed current expectations [1] - As peers in the industry are expected to miss profit expectations in Q4 2025, capital is likely to flow back to WuXi Biologics [1] Group 3: Market Position and Valuation - WuXi Biologics remains the preferred stock in the mainland CRO/CDMO sector according to the report [1] - The company's valuation is at a discount compared to global peers, indicating potential for upward adjustment [1] - The target price for WuXi Biologics is set at 48.5 yuan, with a rating of outperforming the market [1]

Group 1 - The core viewpoint of the report is that WuXi Biologics (02269) has outperformed its mainland CRO peers and the overall healthcare sector since January 20 [1] - The company is considered to have relative resilience due to a more diversified shareholder structure, which helps buffer against geopolitical risks [1] - There is an increased visibility of accelerated growth before 2026, with potential performance possibly exceeding current expectations [1] Group 2 - As competitors in the CRO/CDMO sector are expected to underperform in Q4 2025, capital is likely to flow back to WuXi Biologics [1] - WuXi Biologics remains the preferred stock in the mainland CRO/CDMO space, with a valuation discount compared to global peers [1] - The target price for WuXi Biologics is set at 48.5 yuan, with a rating of outperforming the market [1]

Core Viewpoint - Since January 20, WuXi Biologics has outperformed its mainland CRO peers and the overall healthcare sector, indicating its relative resilience in the market [1] Group 1: Company Performance - WuXi Biologics has shown better stock performance compared to mainland CRO peers and the overall healthcare sector since January 20 [1] - The company benefits from a more diversified shareholder structure, which helps buffer against geopolitical risks [1] Group 2: Growth Potential - There is an increased visibility for accelerated growth by 2026, suggesting potential performance may exceed current expectations [1] - As peers in the industry failed to meet profit expectations in Q4 2025, capital is flowing back to WuXi Biologics [1] Group 3: Market Position and Valuation - WuXi Biologics remains the preferred stock in the mainland CRO/CDMO sector according to the report [1] - The company's valuation is at a discount compared to global peers, indicating potential for upside [1] - The target price set for WuXi Biologics is HKD 48.5, with a rating of "outperform" [1]

Core Viewpoint - Daiwa reports that WuXi Biologics (02269) and WuXi AppTec (02268) plan to make a full acquisition offer for at least 60% of the shares of Easton Biopharma (01875) for a maximum cost of approximately 2.8 billion yuan, with the expectation that Easton Biopharma will maintain its listing status after the acquisition [1] Group 1 - The acquisition is expected to help WuXi AppTec expand its business and gain additional operational production capacity in China [1] - The deal aims to enrich the project portfolio and expand the customer base for WuXi AppTec [1] - This acquisition is anticipated to strengthen WuXi AppTec's leading market position in the ADC contract research and manufacturing organization sector [1] Group 2 - Daiwa currently assigns a "Buy" investment rating to WuXi Biologics [1]

Group 1 - The core viewpoint of the article is that WuXi Biologics (02269) and WuXi AppTec (02268) have announced a comprehensive acquisition offer to acquire at least 60% of the shares of Easton Biopharma (01875) for a maximum price of approximately 2.8 billion yuan [1] - The acquisition is expected to help WuXi AppTec expand its business and gain additional operational production capacity in China, further enriching its project portfolio and expanding its customer base [1] - The acquisition is anticipated to solidify WuXi AppTec's leading market position in the field of ADC contract research and manufacturing organizations [1] Group 2 - Daiwa currently gives a "Buy" investment rating for WuXi Biologics [1]

Company Update - The company participated in the 44th J.P. Morgan Healthcare Conference, where CEO Dr. Chen Zhisheng updated on the business status for 2025 and provided an outlook for accelerated growth in 2026 [1] - The number of new projects signed in 2025 reached a historical high of 209, surpassing 151 in 2024, with approximately half of the new projects coming from U.S. clients [1] - By the end of 2025, the total number of projects is expected to increase to 945, including 74 Phase III clinical projects and 25 commercial production projects, laying a solid foundation for sustained long-term commercial revenue growth [1] Industry Insights - The complex molecule sector shows high industry prosperity, with about two-thirds of the new projects in 2025 being bispecific antibodies and ADCs, indicating a sustained increase in global outsourcing demand for complex molecules [1] - The bispecific antibody business performed exceptionally well, with the number of projects increasing to 196, contributing nearly 20% of the group's revenue, and a year-on-year growth rate exceeding 120% [1] - The ADC pipeline also maintained strong expansion, with the number of projects increasing by 30% year-on-year to 252 [1] - The company is expected to benefit from structural upgrades in the industry as proprietary technology platforms like CD3 TCE continue to advance, enhancing technical barriers and customer stickiness [1] Commercialization and Global Strategy - In 2025, the company completed 28 PPQ projects, a year-on-year increase of 75%, with 34 PPQ projects scheduled for 2026 based on existing contracts [2] - The acceleration of PPQ projects is anticipated to gradually translate into increased CMO revenue and profit release as the number of Phase III and commercial projects rises [2] - The Singapore WuXi AppTec production base was completed on schedule in June 2025, and a strategic partnership with Qatar was established by the end of 2025 to enhance global operational resilience [2] Profit Forecast and Valuation - The profit forecast for 2025 remains unchanged, while the adjusted profit expectation for 2026 has been raised by 4.8% to 5.85 billion yuan, with a new forecast for 2027 set at 6.55 billion yuan [2] - The current stock price corresponds to adjusted P/E ratios of 29.7x for 2025, 25.5x for 2026, and 22.2x for 2027, with a target price increase of 25% to 45 HKD, reflecting an upward potential of 12.5% [2]

Core Viewpoint - WuXi Biologics (2269.HK) experienced a 3.4% decline, closing at HKD 38.66, following the announcement of a block trade agreement involving its major shareholder, Biologics Holdings [1] Group 1 - Biologics Holdings has entered into a block trade agreement with Morgan Stanley to sell 150 million shares of WuXi Biologics [1] - The shares being sold represent approximately 3.63% of the total issued share capital of the company [1] - The sale price is set at HKD 38.52 per share, which reflects a discount of 3.75% compared to the closing price of HKD 40.02 on the previous day [1] Group 2 - The total amount involved in the transaction is approximately HKD 5.778 billion [1]